Breast cancer was the second most frequent cause of new cancer cases worldwide in 2024, and up to 20% of cases fall under the subtype of triple-negative breast cancer (TNBC), one of the most aggressive and difficult subtypes to treat.
Ascentage Pharma Group Corp. Ltd. said two of its novel candidates have been included in the 2025 Chinese Society of Clinical Oncology Guidelines, including its in-house developed Bcl-2 selective inhibitor, lisaftoclax (APG-2575), which is under review in China and could be the first domestically approved Bcl-2 inhibitor and the second global approval.
Ascentage Pharma Group Corp. Ltd. said two of its novel candidates have been included in the 2025 Chinese Society of Clinical Oncology Guidelines, including its in-house developed Bcl-2 selective inhibitor, lisaftoclax (APG-2575), which is under review in China and could be the first domestically approved Bcl-2 inhibitor and the second global approval.
Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or adaptive changes over time can result in resistance to treatment and disease relapse. Researchers from Newave Pharmaceutical Inc. and collaborators described the preclinical efficacy of LP-118, a Bcl-2 inhibitor, in venetoclax-resistant models of CLL.
China’s National Medical Products Administration (NMPA) has accepted Ascentage Pharma Group Corp. Ltd.’s NDA for its in-house-developed Bcl-2 selective inhibitor, lisaftoclax (APG-2575), which could be the first domestically approved Bcl-2 inhibitor in China and the second global approval.
Fochon Biosciences Ltd. has divulged apoptosis regulator Bcl-2 (D103E mutant and D103Y mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.
Fochon Biosciences Ltd. has discovered new apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Tuberculosis still kills a lot of people worldwide (1.6 million deaths per year). Previous findings demonstrated that induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors reduced the growth of Mycobacterium tuberculosis in human macrophages, but when inhibiting multiple proteins from the Mcl-1/Bcl-2 family, the result was more effective and in a more complex human in vitro granuloma environment.
